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ABSTRACT 
         Altered expression of cytokines in response to body injury has diverse actions that can 
exacerbate, mediate, reduce or inhibit neuronal and myelin damage as well as influence the 
disease development in a variety of nervous system disorders, such as Alzheimer’s disease 
(AD), multiple sclerosis and Guillain-Barré Syndrome (GBS). In these studies, we attempted to 
explore the possible roles of tumor necrosis factor (TNF)-α and interleukin (IL)-18 in 
experimental neurodegenerative and neuroinflammatory disorders. 
         The role of TNF-α in kainic acid (KA)-induced excitotoxic neurodegeneration has been 
studied by comparing TNF receptor 1 (TNFR1) knockout (TNFR1-/-) mice with wild-type 
(WT) mice. After nasal application of KA, TNFR1-/- mice showed significantly severer 
seizures than WT mice. In addition, obvious neuronal damage, enhanced microglial activation 
and astrogliosis in hippocampus as well as increased locomotor activity were found in TNFR1-
/- mice compared with WT controls. Moreover, CC chemokine receptor 3 expression on 
activated microglia was increased in TNFR1-/- mice after KA treatment as measured by flow 
cytometry. These data suggest that TNF-α may play a protective role via TNFR1 signalling in 
KA-induced neurodegeneration. 
         Epidemiological studies concerning gender differences in AD support the higher 
prevalence and incidence of AD in women. The influence of age and gender on excitotoxic 
neurodegeneration has been investigated by treating C57BL/6 mice (aged females and males as 
well as adult females and males) with KA. The results showed that aged female mice were 
more sensitive to KA-induced excitotoxicity associated with severer seizure activity, increased 
locomotion and rearing in open-field test, prominent hippocampal neuronal damage, enhanced 
astrocyte proliferation compared with aged males, adult females and adult male mice, 
respectively. In addition, higher level of brain-derived neurotrophic factor in hippocampi of 
aged female mice was observed. These results denote that aged female mice are more sensitive 
to KA-induced excitotoxicity. 
         IL-18 participates in the fundamental inflammatory processes, especially during aging. 
Based on the above results, we were interested in studying the role of IL-18 in KA-induced 
neurodegeneration in aged female C57BL/6 mice. We found that aged female IL-18-/- and WT 
mice showed similar responses to KA insult as demonstrated by comparable seizure activities, 
behavioral changes and neuronal cell death. However, aged female IL-18-/- mice failed to 
exhibit as strong microglial activation as WT mice. Interestingly, even though the number of 
activated microglia was less in KA-treated IL-18-/- mice than in KA-treated WT mice, the 
proportion of microglia that expressed the cytokines, TNF-α, IL-6 and IL-10 was higher in KA-
treated IL-18-/- mice. Deficiency of IL-18 attenuates microglial activation after KA-induced 
excitotoxicity in aged brain, while the net effects of IL-18 deficiency are balanced by the 
enhancement of TNF-α, IL-6 and IL-10 production. 
         To further explore the role of IL-18 in the neurodegeneration and neuroinflammation, 
another animal model - experimental autoimmune neuritis (EAN) was induced by immunization 
of mice (IL-18-/-) with P0 protein peptide 180-199. The clinical course was not significantly 
different between IL-18-/- and WT mice. The splenic mononuclear cell (MNC) proliferation 
was also similar in both animal groups. However, the percentages of interferon-γ, IL-10 and IL-
12 positive cells were decreased among infiltrating MNC of cauda equina in IL-18-/- mice. This 
indicates that IL-18 deficiency inhibits the production of both Th1 and Th2 cytokines in the 
target organ of EAN. 
         In summary, TNF-α may play a protective role via TNFR1 signalling in KA-induced 
neurodegeneration, while IL-18 may not be a key inflammatory cytokine in experimental 
neurodegenerative and neuroinflammatory disorders. 
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1 INTRODUCTION 
1.1 PART I:  KAINIC ACID-INDUCED NEURODEGENERATIVE ANIMAL 
MODEL 
1.1.1 Overview of Excitotoxicity Induced by L-Glutamate  
             L-glutamate, the major excitatory transmitter in the brain and spinal cord, is 
associated with learning, cognition, memory and neuro-endocrine functions [1, 2]. The 
glutamate receptors can be divided into two broad categories: the ionotropic receptors 
that mediate fast postsynaptic potentials by activating ion channels directly, and the 
metabotropic receptors that results in the expression of slow postsynaptic potentials 
through second messengers [3, 4]. The action of glutamate on the ionotropic receptors 
is always excitatory [5, 6]. There are three major subtypes of ionotropic glutamate 
receptors: α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA), kainate, and 
N-methyl-D-aspartate (NMDA), named according to the types of synthetic agonists that 
activate them, respectively [7, 8]. The NMDA glutamate receptor is blocked by specific 
antagonists such as D(-)-2-amino-5-phosphonovalerate (APV) [9, 10]. Both AMPA and 
kainate receptors are blocked by 6-cyano-7-nitroquinoxalin-2,3-dione (CNQX) [11, 
12]. Thus the AMPA and kainate receptors are sometimes referred to together as non-
NMDA receptors. The ion channel of NMDA receptor is a tetrameric structure that 
results from up to seven genes coding for seven subunits termed GluN1, GluN2A, 
GluN2B, GluN2C, GluN2D, GluN3A and GluN3B [13, 14]. The AMPA receptor 
family is composed of four subunits, GluA1–4 [15, 16]. The kainate receptor family 
comprises five genes, divided into two subfamilies, including GluK4-5 and GluK1–3. 
GluK4 and GluK5 exhibit higher affinity for kainate than GluK1–3 [17, 18]. Herein, 
we used the new nomenclature for glutamate receptors recommended by the 
International Union of Pharmacology Committee on Receptor Nomenclature and Drug 
Classification (NC-IUPHAR) [19]. NC-IUPHAR recommended and previous 
nomenclatures of ionotropic gluatamate receptor subunits are listed in Table 1. 
             Excessive amounts of glutamate are highly toxic to neurons, an action termed 
glutamate excitotoxicity [20, 21]. Glutamate excitotoxicity is triggered primarily by 
excessive Ca2+ influx arising from overstimulation of the NMDA subtype of glutamate 
receptors, followed by the generation of reactive oxygen species (ROS) as well as 
mitochondrial dysfunction, leading to neuronal apoptosis and necrosis [22, 23]. There is 
increasing realization that the mitochondrial dysfunction occupies the center stage in 
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these processes [23, 24]. In many cell types, glutamate neurotoxicity is induced by 
NMDA as well as non-NMDA receptors [20, 21, 25]. 
 
Table 1. NC-IUPHAR recommended and previous nomenclatures of ionotropic gluatamate 
receptor subunits.   
 
Ionotropic 
glutamate 
family 
NC-IUPHAR 
subunit 
nomenclature 
Previous nomenclatures Human 
gene 
name 
Human 
chromosomal 
location 
NMDA GluN1 GLUN1, NMDA-R1, NR1, GluRξ1 GRIN1 9q34.3 
GluN2A GLUN2A, NMDA-R2A, NR2A, GluRε1 GRIN2A 16p13.2 
GluN2B GLUN2B, NMDA-R2B, NR2B, hNR3, GluRε2 GRIN2B 12p12 
GluN2C GLUN2C, NMDA-R2C, NR2C, GluRε3 GRIN2C 17q25 
GluN2D GLUN2D, NMDA-R2D, NR2D, GluRε4 GRIN2D 19q13.1 
GluN3A GLUN3A, NMDA-R3A, NMDAR-L, chi-1 GRIN3A 9q31.1 
GluN3B GLUN3B, NMDA-R3B, GRIN3B 19p13.3 
AMPA GluA1 GLUA1, GluR1, GluRA, GluR-A, GluR-K1, HBGR1 GRIA1 5q31.1 
GluA2 GLUA2, GluR2, GluRB, GluR-B, GluR-K2, HBGR2 GRIA2 4q32-q33 
GluA3 GLUA3, GluR3, GluRC, GluR-C, GluR-K3 GRIA3 Xq25-q26 
GluA4 GLUA4, GluR4, GluRD, GluR-D GRIA4 11q22 
Kainate GluK1 GLUK5, GluR5, GluR-5, EAA3 GRIK1 21q22.11 
GluK2 GLUK6, GluR6, GluR-6, EAA4 GRIK2 6q16.3-q21 
GluK3 GLUK7, GluR7, GluR-7, EAA5 GRIK3 1p34-p33 
GluK4 GLUK1, KA1, KA-1, EAA1 GRIK4 11q22.3 
GluK5 GLUK2, KA2, KA-2, EAA2 GRIK5 19q13.2 
 
1.1.2 KA Administration Induces Recurrent Seizures in Rodents 
Kainic acid (KA) is a non-degradable analog of glutamate and 30-fold more 
potent in neurotoxicity than glutamate [26, 27].  Administration of KA to rodents 
caused a well characterized seizure syndrome, as described by Ben-Ari and other 
research groups [28, 29]. The seizure activity caused by intravenous, intraperitoneal 
injections or microinjection into amygdala or hippocampus is divided in several 
distinct phases. During the first 20-30 min, the animals have “staring” spells, followed 
by head nodding and numerous wet-dog shakes for another 30 min. One hour after KA 
administration, the animal starts recurrent limbic motor seizures, including masticatory 
and facial movements, forepaws tremor, rearing and loss of postural control. The 
seizures then become progressively severer, with a reduction in the intermission. In the 
following l-2 h, the animal displays a full status epilepticus [28-30]. In the past few 
years, our research group has developed a model of KA-induced hippocampal injury 
by intranasal administration of KA into C57BL/6 mice [31, 32]. Within 15 min after 
intranasal administration, the C57BL/6 mice are catatonic and staring. Myoclonic 
twitching and frequent rearing and falling follow this behavior. Within 30-40 min after 
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administration, the mice have continuous tonic-clonic seizures, which continued for 1-
5 h. Some serious cases die in this period. After 5 h of administration, mice assume a 
hunched posture and are immobile for the next few hours.  
 
1.1.3 KA Treatment Changes Behaviors of Rodents 
            CA1 pyramidal neurons receive two distinct excitatory inputs that are capable of 
influencing hippocampal output and involving in spatial memory and memory 
consolidation [33, 34]. Damage in CA1/CA3 region of hippocampus induced by KA 
mainly results in the spatial learning deficits [35, 36]. KA-treated Wistar rats are 
impaired in the water maze and object exploration tasks, and hyperactive in the open 
field test, which can be improved by physical exercise and the selective 
cyclooxygenase (COX)-2 inhibitor [37, 38].  Intraperitoneal injections of KA into the 
developing rat brains induce the impaired short-term spatial memory in the radial-arm 
maze, deficient long-term spatial learning and retrieval in the water maze, and a greater 
degree of anxiety in the elevated plus maze [39, 40]. Mice with a single unilateral 
injection of KA into the dorsal hippocampus exhibit a decrease in depression-like 
behavior in the forced swimming test and retarded acquisition as well as impaired 
retention of visual-spatial information in the Morris water maze test [41]. Our research 
group also reported that intranasal KA administration to C57BL/6 mice induced the 
elevated level of spontaneous activity in the open field test [31, 32].  
 
1.1.4 KA Insult Causes Hippocampal Neurodegeneration 
             Systemic injection of KA to rodents caused the selective neuronal vulnerability  
in the hippocampus, as reviewed by the research groups of Ratte and Wang [42, 43]. 
The hilar neurons are sensitive to KA-induced neurotoxicity, but neuron loss in the 
other areas of the hippocampus differs between animal species and strains [44-46]. In 
rats, the systemic injections of KA produced widespread neuronal death, primarily in 
the hippocampus hilus, CA1 and CA3 areas [25, 47].  High doses of KA can also 
induce neurotoxicity in the medial amygdaloid nuclei [48]. Mouse strains vary 
significantly in their sensitivity to KA-induced neurodegeneration [45, 46, 49, 50]. In 
general, the C57BL/6, C57BL/10, and (C57BL/6 x CBA/J) F1 strains are resistant to 
KA-induced neurodegeneration, while the FVB/N, ICR and DBA/2 J strains are 
vulnerable [46]. Systemic administration of KA to mice leads to neuronal damage, 
mainly in the hippocampus [32, 43, 45]. The vulnerable mice, such as FVB/N and 
DBA/2J, show extensive degeneration in most of the brain regions, including the 
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neocortex, striatum, hippocampus, and nuclei in thalamus, hypothalamus and amygdale 
[46]. C57BL/6, the “relatively” resistant mouse strain, reveals significant neuronal 
damage in CA1 and CA3, and to a lesser extent, in the polymorphic layer of the dentate 
gyrus by 12 h post-treatment of KA systemically detected by cupric-silver and Fluoro-
Jade B staining [51, 52].  Utilizing the traditional Nissl staining, we found that neuronal 
damage was restricted to the hippocampus, especially CA3 area 1 day after intranasal 
KA treatment [31, 32]. CA3 region has the highest abundance of kainate receptors, the 
activation of which can elevate the concentration of ROS and impair the normal 
function of mitochondria [53-55]. CA3 neurons are directly excited by stimulation of 
their KA receptors and indirectly, by increased glutamate efflux secondary to KA 
stimulation of mossy fibers [56, 57]. CA3 synchronization produces spreading 
epileptiform activity that extends to CA1 and other limbic structures [58, 59].  
 
1.1.5 KA Mediates the Generation of Oxidative Stress 
            KA receptors have both presynaptic modulatory and direct postsynaptic 
excitatory actions [60, 61]. The activation of KA receptors produces membrane 
depolarization and results in alteration in intracellular calcium concentrations, which is 
required to trigger the neuronal death cascade (Figure 1) [62]. KA can also induce the 
release of lactate dehydrogenase (LDH), and a decrease in 3-(4, 5-dimethylthiazole-2-
yl)-2, 5-diphenyl tetrazolium bromide (MTT), which result in damage of 
mitochondrial function [43]. KA administration increases the generation of ROS 
and reactive nitrogen species (RNS). There is growing evidence that free radical 
generation plays a key role in the neuronal damage [63]. KA has been shown to 
immediately induce COX-2 expression that might be involved in hippocampal neuronal 
death, while COX-1 might participate in KA-induced cortical neuronal death [64]. 
Early induced COX-2 facilitates the recurrence of hippocampal seizures, and late 
synthesized COX-2 stimulates hippocampal neuron loss after KA administration [65]. 
COX-2 knockout mice are resistant to neuronal death after KA treatment [66]. COX 
catalyzes the first step in the synthesis of prostanoids, including prostaglandins (PGs), 
prostacyclin, and thromboxanes. PGE(2) is pathologically increased in the brain after 
KA treatment, and has been proven to be closely associated with neuronal death [67].  
In addition, lipid peroxides play critical roles in the initiation and modulation of 
inflammation and oxidative stress upon KA insult. Seizures can induce the products of 
lipid peroxidation, such as F(2)-isoprostanes and Isofurans, which have been thought to 
be the reliable indices of oxidative stress in vivo [68]. 
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Figure 1. Schematic overview of KA-mediated neuronal death. 
 
1.1.6 Glial Cells Are Activated upon KA Injury  
             KA-induced neuronal death is accompanied by increased activation of 
microglia and astrocytes [32, 69, 70]. Additionally, the activated glial cells cluster at 
the hippocampal lesions and the immunostaining reactivity is particularly strong around 
areas of debris (Figure 2).  
  
1.1.6.1   Microglia 
         Microglia account for approximately 20% of the total glial population in the 
central nervous system (CNS). Microglia are the main effector cell type of the immune 
and inflammatory responses in the CNS, as earlier reviewed by Streit and his 
colleagues [71]. The normal role of microglia could be partly connected to 
neuroprotection, whereas in pathological conditions microglia may become disease-
promoting cells. Upon neuronal injury, microglia rapidly acquire changes in 
morphology and secrete a variety of soluble mediators [72, 73]. Some studies suggested 
that the activated microglia might exert a neuroprotective function, especially in 
multiple sclerosis (MS) and its animal model, experimental autoimmune 
encephalomyelitis (EAE) by creating a microenvironment for reparative and 
regenerative processes [74]. Evidence is also accumulating that activated microglia 
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induce and/or exacerbate neuropathological changes in several CNS diseases such as 
Alzheimer’s disease (AD) and Parkinson’s disease (PD) through secreting 
proinflammatory and neurotoxic factors [75, 76]. In KA-induced hippocampal 
neurodegeneration, microglial activation is generally believed to contribute to the 
neuronal death [70, 77, 78]. A recent study showed that IκB kinase/nuclear factor kappa 
B (NF-κB) dependent microglial activation participated in KA-mediated injury in vivo 
through induction of inflammatory mediators [77]. However, whether microglial 
activation initiates the disease progression or merely responds to neuronal death is still 
unclear.  
 
1.1.6.2 Astrocytes 
              Astrocytes, the most numerous glial cells, have been regarded as passive 
supporters of neurons in CNS for decades. Studies of the last 20 years, however, 
challenged this assumption by demonstrating that astrocytes possess functional 
neurotransmitter receptors [79, 80]. These findings have led to a new concept of 
neuron-glia intercommunication where astrocytes play an undoubted dynamic role by 
integrating neuronal inputs and modulating synaptic activity, and so contribute to 
disease development [81]. Astrocytes have functional receptors for the excitatory 
neurotransmitter glutamate and respond to physiological concentrations of this 
substance with oscillations in intracellular Ca2+ concentrations and spatially 
propagating Ca2+ signals [82-84]. The expression of glial fibrillary acidic protein 
(GFAP) has been shown to steadily increase from one/three days up to one month after 
intra-hippocampal or intraperitoneal injection of KA [85, 86]. Astrogliosis induced by 
excitotoxicity has been considered as a marker for neurotoxicity [69, 87]. It is believed 
that astrocytes produce growth factors to prevent neurons from death and to promote 
proliferation and differentiation of precursor cells [88-90]. Activation of transcription 
factors, including nuclear factor erythroid-2-related factor 2 (Nrf2) and NF-κB, in 
astrocytes induces the neuroprotective molecule expression and confers protection to 
neighboring neurons [91-93]. Old astrocyte specifically induced substance (OASIS) is 
involved in the endoplasmic reticulum stress response [94]. A recent study showed that 
OASIS expressed in astrocytes plays important roles in protection against neuronal 
damage induced by KA [95]. 
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1.1.7 Altered Cytokine Expression Affects KA-Induced Injury 
                     Altered expression of cytokines in response to brain injury has diverse actions 
that can exacerbate, mediate, reduce or inhibit neuronal damage and influence the 
disease development in a variety of CNS disorders, such as AD, MS, viral or bacterial 
infections, ischemia, stroke, and various forms of encephalopathies [96-100]. Cytokines 
can be divided into pro-inflammatory and anti-inflammatory cytokines, which play the 
neurodestructive and neuroprotective roles, respectively. It is the balance between  
destructive and protective factors that ultimately determines the net result of the neuro-
immune and neuro-inflammation interaction, as reviewed by Kerschensteiner and his 
co-workers [101]. Results from studies using KA model also indicated that 
manipulation of pro- and anti-inflammatory cytokines can modify the outcome with 
Figure 2. Glial cells activation 
accompanied neuronal death 7 
days after KA (45 mg/kg body 
weight) treatment to C57BL/6 
mice. (A) Obvious neuron loss 
was showed in CA3 area of 
hippocampus by Nissl´s 
staining. (B) CD11b positive 
cells (microglia) accumulated 
in the lesioned CA3 area. (C) 
GFAP positive cells 
(astrocytes) spread the whole 
hippocampus, especially in 
CA3 area. 
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regard to the seizure activity, behavioral changes as well as the neuropathological 
consequences [32, 102-104].  
 
1.1.7.1 TNF-α 
              Tumor necrosis factor-α (TNF-α) is mainly produced by microglia and 
astrocytes in the CNS. Its functions are mediated through two receptors, TNF receptor 
(TNFR) 1 (p55) and TNFR2 (p75), both of which are expressed on various cells types 
[105]. TNF-α over-expression participates in the pathogenesis of several CNS 
disorders, such as AD [106], bacterial meningitis [107], MS [108] and cerebral malaria 
[109]. TNF-α potentiates excitotoxic injury to human fetal brain cells [110]. In contrast 
to its well known deleterious roles, multiple lines of evidence suggested that TNF-α 
also exhibit neuroprotective properties. This implies an intricate biological function of 
TNF-α in modulating immune and inflammatory responses. TNF-α knockout worsens 
Listeria infection in the CNS [111] and TNF-α receptor knockout enhances the 
neuronal damage after excitotoxic [103, 112], ischemic [113] or traumatic injury [114]. 
Several neuroprotective molecules were identified as TNFR1 targets, including 
members of the Bcl-2 family, DNA repair machinery and cell cycle, developmental, 
and differentiation factors, neurotransmitters and growth factors, as well as their 
receptors [115]. The mechanisms by which TNF reduced neuron loss after brain injury 
may involve the up-regulation of proteins, such as neuronal apoptosis inhibitor protein 
(NAIP), which maintain calcium homeostasis and reduce free radical generation [116]. 
Study also proved that the protective roles of TNF-α in KA-induced neurodegeneration 
are via TNFR2 signalling [112].  
 
1.1.7.2 IL-18 
               Interleukin (IL)-18 is most closely related to IL-1β. The similarities between 
both cytokines comprise structure, receptor complex, and pro-inflammatory properties 
[117]. IL-18 serves as a link between innate and adaptive immune responses, such as 
stimulating the expression of adhesion molecules, inducing the production of 
chemokines (IL-8) and cytokines (TNF-α and IL-6), stimulating the activity of NK 
cells, and promoting T helper 1 (Th1) cells  responses in combination with IL-12, Th2 
responses in combination with IL-4, and Th17 responses in combination with IL-23 
[118]. IL-18 and IL-18 receptor (IL-18R) mRNA have been found in brain tissue and in 
cultured astrocytes and microglia [119]. IL-18 enhanced postsynaptic AMPA receptor 
responses in CA1 pyramidal neurons via the release of glutamate, thereby facilitating 
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basal hippocampal synaptic transmission [120]. IL-18 deficient mice showed a 
diminished microglial activation and reduced dopaminergic neuron loss after acute 1-
methy-4-phenyl-1,2,3,6-tetrahydropyridine treatment [121]. The roles of IL-18 in KA-
induced model are controversial.  Levels of IL-18 and IL-18R in hippocampus increase 
progressively from day 1 and peaked at day 3 post-KA treatment [122]. Interestingly, 
intracerebellar coinjection of IL-18 counteracts the effect of IL-1β in KA-induced 
ataxia in mice [123]. We showed that exogenous IL-18 administration aggravated the 
KA-induced injury in normal C57BL/6 mice, while in the condition of IL-18 
deficiency, IL-12 could overcompensate the function of IL-18 and worsen the seizure 
activity as well as hippocampal neurodegeneration [32].  
 
1.1.8 Influence of Aging and Gender on KA-induced Injury 
Accumulating results have demonstrated an increased sensitivity of aged 
individuals to excitotoxic neurodegeneration [52, 124, 125]. The currents induced by 
AMPA displayed a significant increase with age, which might mediate neurotoxicity 
associated with age-related neuropathies [126]. Aged CA1 failed to exhibit any 
tolerance to domoic acid (DOM) following preconditioning [127]. Several factors that 
change with age might influence brain sensitivity to excitotoxic damage, including the 
density of glutamate receptors, the uptake and release of neurotransmitters, and cellular 
metabolic processes [128]. Significant decreases have been detected for the NMDA and 
kainate receptor binding sites in most of the cortical areas in aging mice [129]. 
           There is a gender-associated sensitivity in the aged brain to the 
neurodegeneration [130], which might involve alterations in estrogen levels or aged-
related decline in the activity of NMDA receptors. Aged female Long-Evans (LE) rats 
show greatly enhanced susceptibility to KA-induced seizures even at doses four-fold 
lower than that of adult controls [125].  After injections of KA into the hippocampus of 
rats, only females exhibited the increase in daily food intake and body weight [131]. 
Estrogen can profoundly improve spatial reference memory in aged females and this 
improvement may be related to enhanced hippocampal synaptic plasticity [132]. The 
epidemiological studies concerning gender differences in AD also support the higher 
prevalence and incidence of AD in women [133, 134]. A recent study using positron 
emission tomography explored gender differences in the regional cerebral metabolic 
rate of glucose in the patients with AD and found that, at the same level of severity of 
cognitive impairment, men showed a significantly greater hypometabolism than 
 10 
women. This suggests that men can compensate more pathological changes than 
women and men are less likely to express neurodegeneration as clinical dementia [135].  
 
1.1.9 Therapeutic Strategies 
             Considering that oxidative stress is central to KA-induced excitotoxic damage, 
anti-oxidant and anti-inflammatory treatments may attenuate or prevent the KA-
mediated neurodegeneration (Figure 3). The potential role of COX-2 inhibitors as a 
new therapeutic drug for the neuron loss after KA treatment has been studied. The 
selective COX-2 inhibitors, celecoxib, NS398, rofecoxib and SC58125, can suppress an 
elevation of PGE(2) and block hippocampal cell death [37, 66]. Free radical scavengers 
are well known to prevent neuron loss induced by exposure to excitotoxins. Edaravone 
(Ed), a newly developed free radical scavenger, could inhibit lipid peroxidation and 
prevent neuron loss when administered after the onset of seizures in a KA-induced 
neurodegenerative animal model [136]. The pineal secretory product, melatonin, has 
free-radical-scavenger and antioxidant properties, which attenuates KA-induced 
neuronal death, lipid peroxidation, and microglial activation [137]. Several 
phospholipase A (2) inhibitors, quinacrine and chloroquine, arachidonyl 
trifluoromethyl ketone, bromoenol lactone, cytidine 5-diphosphoamines, and vitamin E, 
have been shown to prevent the neurodegeneration in KA-mediated neurotoxicity 
[138]. The other drugs tested experimentally include fluoxetine, ethyl pyruvate and 
statins, whose neuroprotective effects are associated with their anti-inflammatory 
effects. The transcription factor Nrf2 can guard the redox homeostasis and demonstrate 
its antioxidant properties against excitotoxicity, which has also been pharmacologically 
targeted to prevent KA-induced neuronal death [139]. Since glutamate excitotoxicity 
contributes to a variety of disorders in the CNS, the anti-oxidant and anti-inflammatory 
drugs merit further investigation. Additionally, targeting the pro-inflammatory 
cytokines, by blocking the unique signal transduction of the specific cytokine is another 
potential therapeutic strategy.  
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Figure 3.  Schematic illustration of anti-oxidant and anti-inflammatory treatments 
to KA-mediated neuronal death.  
 
1.2 PART II: GUILLAIN-BARRÉ SYNDROME AND ITS ANIMAL MODEL  
          Guillain-Barré syndrome (GBS) is an immune-mediated inflammatory disease of 
the peripheral nerves, involving both myelin sheath and axons. It is the most common 
cause of the acute flaccid paralysis worldwide [140]. GBS is characterized by acute 
progressive and symmetrical motor weakness of the extremities as well as of bulbar and 
facial musculature. The progressive phase of syndrome lasts from a few days to four 
weeks [141]. Approximately 85% of patients with GBS achieve a full functional 
recovery within 6 to 12 months. Some patients have persistent weakness, areflexia and 
paresthesia [142]. GBS is considered as an organ-specific immune-mediated 
inflammatory disorder emerging from a synergistic interaction of cellular and humoral 
immune response to the peripheral nerve antigens [143]. In GBS, activated T cells and 
macrophages in circulation cross the blood-nerve barrier and initiate an inflammation in 
the peripheral nervous system (PNS), which results in demyelination and axonal loss. 
Cytokines and chemokines, adhesion molecules, nitric oxide, and matrix 
metalloproteinases (MMP) contribute to this process. 
          Experimental autoimmune neuritis (EAN) is a CD4+ T cell-mediated 
demyelinating inflammatory disease of the PNS, which serves as an animal model for 
the human GBS. EAN can be induced in rats, mice, rabbits and monkeys by active 
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immunization with whole peripheral nerve homogenate, myelin proteins P0 or P2 and 
their neuritogenic peptides [144-146], and by adoptive transfer of P0 and P2 as well as 
their peptide-specific CD4+ T cell lines [147, 148]. The pathological hallmark of EAN 
is the infiltration of the PNS by inflammatory cells including lymphocytes and 
macrophages, which results in multifocal demyelination of axons. The course of EAN 
appears to be determined by the temporally and spatially regulated expression of 
various cytokines produced by infiltrating immune cells and Schwann cells [149, 150].  
     Cytokines involved in the pathogenesis of EAN and GBS include TNF-α, 
interferon-γ (IFN-γ), IL-12, IL-18, IL-10, IL-4 and TGF-β. Th1 cytokines are dominant 
in the inflamed nerves during the acute phase of disease [150, 151]. Elevated serum 
concentration of TNF-α showed a positive correlation with the disease severity in GBS 
patients [152]. IFN-γ receptor knockout mice showed less EAN severity [153]. Both 
IL-12 deficient mice and mice treated with anti-IL-18 monoclonal antibody exhibited 
reduced clinical severity of EAN through impaired Th1 responses in inflamed nerves 
[154, 155]. Treatment by IL-10 ameliorated the inflammatory response in EAN by 
inhibiting Th1 and enhancing Th2 responses [156]. The balance of pro- and anti-
inflammatory cytokines may determine the outcome of EAN. 
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2 AIMS OF THE STUDIES 
 
To identify the role of TNF-α/IL-18 in the experimental neurodegenerative and 
neuroinflammatory disorders. 
 
Specific aims: 
  
Study I:     To study the role of TNF-α in KA-induced neurodegeneration. 
Study II:   To investigate how age and gender affect the susceptibility to KA-induced 
                   excitotoxic neurodegeneration in C57BL/6 mice. 
Study III: To investigate the role of IL-18 in KA-induced neurodegeneration in 
aging condition. 
Study IV: To study the role of IL-18 in EAN. 
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3 METERIALS AND METHODS 
3.1 ANIMALS (STUDIES I-IV) 
          TNFR1 KO mice, male, 5-6-week-old, and the corresponding matched wild-type 
(WT) C57BL/6 mice were used in Study I.  Aged (19-20-month-old) and adult (7-8-
month-old) C57BL/6 mice, both female and male were used in Study II. Aged female 
IL-18 KO mice (18-19-month-old) and young male IL-18 KO mice (4-week-old), were 
used in Studies III and IV, respectively. All mice were housed on a 12-h light-dark 
schedule with water and food available ad libitum. 
 
3.2 KA ADMINISTRATION AND ASSESSMENT OF CLINICAL SIGNS 
(STUDIES I-III)  
          Mice were partially anesthetized with Isofluen. KA dissolved in distilled 
water/saline (10 mg/1.3 ml) was slowly and gently dropped by micropipette into the 
noses of the mice. Doses of KA used were 40 mg/kg body weight in Study I, 20 or 30 
mg/kg in Study II, and 25 mg/kg in Study III. Age- and body weight-matched control 
mice received the same amount of distilled water/saline intranasally as controls. Mice 
were monitored continuously for 5 h to register the onset and extent of seizure activity. 
Seizures were rated as follows: 0, normal; 1, immobilization; 2, rearing and falling; 3, 
seizure for less than 1 h; 4, seizure for 1-3 h; 5, seizure for more than 3 h; and 6, death. 
 
3.3 INDUCTION OF EAN AND ASSESSMENT OF CLINICAL SIGNS 
(STUDY IV) 
         The neuritogenic P0 protein peptide 180-199, corresponding to amino acids 180-
199 of rat PNS myelin P0 protein was synthesized by solid-phase stepwise elongation 
using a Tecan/Syro peptide synthesizer (Multisyntech, Bochum, Germany). Mice were 
immunized twice on days 0 and 7 post-immunization (p.i.) by subcutaneous injection of 
120 µg of P0 peptide 180-199 and 0.5 mg of Mycobacterium tuberculosis (Difco, 
Detroit, USA) in 25 µ l saline and 25 µ l Freund’s incomplete adjuvant (ICN 
Biomedicals, Aurora, USA). All mice received 400, 200, and 200 ng pertussis toxin 
(Sigma, St. Louis, USA) by intravenous injection on days -1, 0 and +2 p.i., 
respectively. Clinical signs of EAN was assessed immediately before immunization 
(day 0) and thereafter every second day until day 27 p.i. and scored as follows: 0, 
normal; 1, flaccid tail, decreased tone in whole tail or mild limb weakness; 2, severe 
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limb weakness or mild hind limb paralysis; 3, moderate hind limb paraparesis; 4, severe 
hind limb paralysis; 5, severe tetraparesis. 
 
3.4 HISTOPATHOLOGICAL ANALYSIS (STUDIES I-IV) 
   The surviving KA-treated mice as well as water/saline-treated control mice were 
anesthetized with sodium pentobarbital and transcardially perfused with phosphate-
buffered saline (PBS) followed by 4% buffered formaldehyde at different time points 
after administration of KA. The brains were kept in 10% sucrose until being frozen. 
Coronal sections (12-µm slices) from -1.15, -1.94, and -2.80 mm, respectively, relative 
to the bregma were prepared according to the information in Franklin’s brain atlas 
[157]. Sections were stained by Nissl’s method (Studies I-III) and Fluoro-Jade B (FJB) 
staining (Study III) to evaluate degenerating neurons. FJB is an anionic fluorescein 
derivative useful for the histological staining of neurons undergoing degeneration. For 
assessment of severity and extent of neurodegeneration in the hippocampus according 
to Nissl’s staining, sections were scored using a semiquantitative grading system: 0, 
normal; 1, slight shrinkage of neurons (1-4% pyknotic neurons in area CA3); 2, 
moderate shrinkage of neurons (5-15% pyknotic neurons in area CA3); 3, severe 
shrinkage of neurons (more than 15% pyknotic neurons in area CA3); 4, slight loss of 
neurons (5-10% neuron loss in area CA3); 5, moderate loss of neurons (11-40% neuron 
loss in area CA3); and 6, severe loss of neurons (more than 40% neuron loss in area 
CA3). In Study IV, sciatic nerves were dissected, fixed in 4% formaldehyde and 
embedded in paraffin. Multiple longitudinal sections (6-µm slices) were stained with 
haematoxylin-eosin for evaluation of the extent of mononuclear cell (MNC) infiltration. 
Tissue areas were measured by image analysis and the results were expressed as cells 
per mm2 tissue section. 
 
3.5 IMMUNOHISTOCHEMISTRY OF BRAIN SECTIONS (STUDIES I-III)  
          Frozen hippocampal sections were prepared as described for histopathological 
analysis. After washes with Tris buffer, the sections were blocked by “protein block” 
(DAKO A/S, Glostrup, Denmark) at room temperature (RT) for 30 min. Subsequently, 
they were exposed to appropriate primary and secondary antibodies. Sections were 
stained by using the avidin-biotin technique (Vectastain Elite Kit; Vector Labs, 
Burlingame, CA, USA). Peroxidase-substrate solution DAB (Sigma-Aldrich, 
Stockholm, Sweden) was added until the desired intensity of color developed. 
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Omission of primary antibodies and incubation with an isotype matched normal IgG 
served as negative controls.  
 
3.6  ISOLATION AND CULTURE OF MNC AND PROLIFERATION 
ASSAY (STUDY IV) 
          The spleens of mice from each group were removed and single cell suspensions 
of MNC from individual mice were prepared by grinding through a wire mesh. 
Erythrocytes were osmotically lysed. MNC were washed three times before being 
suspended in RPMI-1640 medium with 2 mM glutamine and 25mM HEPES (Gibco, 
Paisley, UK) supplemented with 10% (v/v) fetal bovine serum (FBS) (Gibco) and 50 µ
g/ml gentamycin (Gibco). MNC suspended in 200 µ l portions were cultured in 
triplicates in round-bottomed 96-well polystyrene microtiter plates at a cell density of 2 
×106 cells/ml in a humidified atmosphere with 5% CO2 at 37ºC in the presence of 
P0 180-199 peptide (10 µg/ml), ConA (5 µg/ml, Sigma) or the same volume (10 µl) of 
PBS. After 60 h incubation, cells were pulsed with 3H-methylthymidine (1 µCi/well, 
Amersham, Little Chalfont, UK) and cultured for additional 18 h. Cells were harvested 
onto glass fiber filters (Titertek, Skatron, Lierbyen, Norway). 3H-methylthymidine 
incorporation was measured in a liquid β -scintillation counter and results were 
expressed as counts per minute (cpm). Values used were the means from three separate 
wells. 
 
3.7 ISOLATION AND FCM ANALYSIS OF MICROGLIA (STUDIES I AND 
III) 
         The surviving KA-treated mice, water/saline-treated mice and untreated mice 
were perfused with PBS and sacrificed. The hippocampi were dissected and dissociated 
by pipetting. Next, after trypsinization at 37ºC for 15 min, FBS (10%, final 
concentration) was added to inactivate trypsin activity. The tissues were then 
dissociated with repeated pipetting in Krebs-Ringer buffer (KRB) solution [120 mM 
NaCl, 5 mM KCl, 1.2 mM KH2PO4, 25 mM NaHCO3, 14 mM D-glucose, 2.5 mM 
MgSO4, 0.3% bovine serum albumin (BSA) containing DNase I (Sigma-Aldrich)]. 
Cell suspensions were passed through a 70-µm pore-size strainer and spun down. The 
cell pellets were resuspended in 30% Percoll in PBS and centrifuged at 500 x g for 20 
min. The resulting pellets were resuspended, passed through a 40-µm pore-size strainer, 
collected, and stained for flow cytometry (FCM).   
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         Microglia enriched cell suspensions were washed with PBS containing 1% BSA 
(BSA/PBS), permeabilized, fixed and incubated with the appropriate combinations of 
antibodies. After washing, cells were analyzed by FACSCalibur flow cytometer and 
CellQuest software (both from Becton Dickinson). The percentage of positive cells of 
each molecule on microglia was determined. At each time point, microglia from all 
groups of mice (WT mice with or without KA treatment, and KO mice with or without 
KA treatment) were collected and analyzed on the same day with the same cytometer 
settings.  
 
3.8 ISOLATION AND FCM ANALYSIS OF MNC FROM CE (STUDY IV) 
          Briefly, cauda equina (CE) fragments of spinal cords were carefully removed, 
transferred to RPMI-1640, ground and passed through a 70 µm cell nylon mesh. The 
resultant cells were suspended in 27% percoll in PBS and centrifuged at 1000×g for 30 
min at 4°C. The pellet was washed with BSA/PBS, permeabilized, fixed and incubated 
with the appropriate combinations of antibodies. After washing, cells were analyzed by 
FACSCalibur flow cytometer and CellQuest software. The percentage of the positive 
cells of each molecule on infiltrating MNC was determined. 
 
3.9 OPEN-FIELD TEST WITH ZONE MONITORING (STUDIES I-III)   
          The open field test is used to measure exploratory behavior and spontaneous 
motor activity of the animals. The apparatus consisted of four identical Plexiglas boxes 
(34 x 34 x 18 cm) with a lower and a higher row of photosensors connected to a 
computer that automatically recorded the activity of the animals inside of the arena. 
Light bulbs (25 W) provided the illumination for each arena. Four mice were tested 
simultaneously, one per arena. At the beginning each mouse was placed into the center 
of open-field arena and its locomotion as well as rearing were recorded every 5 min 
during 60 min. Locomotion was registered each time the mouse interrupted the lower 
row of photosensors and rearing was recorded each time it interrupted the higher row. 
All tests were carried out between the hours of 9:00-15:00.  
 
3.10 ELISA (STUDY II) 
          Halves of the hippocampal and cortical samples were homogenized in ice-cold 
lysis buffer, and the total protein, brain-derived neurotrophic factor (BDNF), and nerve 
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growth factor (NGF) levels were measured using the supernatants of the tissue 
homogenate solutions. The total protein level was measured by using the Pierce BCA 
Protein Assay Reagent kit. NGF and BDNF levels were assessed using a commercially 
available ELISA assay kit (Promega, Sweden). Briefly, standard 96-well flat-bottom 
ELISA plates were incubated with the corresponding captured antibody overnight at 
4○C and 1× Block & Sample buffer for 1 h at RT. Wells containing the standard 
proteins and supernatants of brain tissue homogenates were incubated for 6 h at RT. 
They were then incubated with second antibody for 2 h at RT. A species-specific 
antibody conjugated to horseradish peroxidase (HRP) as a tertiary reactant for 1 h at 
RT. A TMB One Solution was used to develop color. This reaction was terminated 
with 1N hydrochloric acid and the absorbance was recorded at 450 nm in a plate reader.  
 
3.11 STATISTICS (STUDIES I-IV) 
          Non-parametric tests (Kruskal-Wallis test for more than two groups and Mann-
Whitney test for comparisons between two groups) were used to analyze the clinical, 
pathological and immunostaining data, and parametric tests was used to analyze flow 
cytometry, ELISA, and behavioral results. All tests were two-tailed. Data are presented 
as mean ± SD for parametric tests and median with percentiles (10% - 90%) for non-
parametric analysis. The level of significance was set at p <0.05. 
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4 RESULTS AND DISCUSSION 
4.1 STUDY I: TNF-α RECEPTOR 1 DEFICIENCY ENHANCES KA-
INDUCED HIPPOCAMPAL INJURY IN MICE 
          After nasal application of a single dose of 40 mg KA per kilogram body weight, 
TNFR1-/- mice showed significantly severer seizures than WT mice. In addition, 
obvious neuronal damage, enhanced microglial activation and astrogliosis in the 
hippocampus as well as increased locomotor activity were found in TNFR1-/- mice 
compared with WT controls on day 8 after KA delivery. Moreover, CC chemokine 
receptor 3 (CCR3) expression on activated microglia were increased on day 3 after KA 
treatment in TNFR1-/- mice measured by flow cytometry.  
          Neuronal injury is the main characteristics of KA-induced excitotoxic 
neurodegeneration. Inflammatory processes, such as the production of cytokines and 
related inflammatory molecules have been implicated in the pathogenesis of KA-
induced neurodegeneration [31, 102]. TNF-α is a pleiotropic inflammatory cytokine 
and appears to play a pivotal role in the inflammatory conditions. Our results showed 
that TNFR1-/- mice exhibited significantly severer seizures and neuronal damage in 
hippocampus than WT mice after KA administration. Consistent with the severer 
neuronal damage, TNFR1-/- mice showed more difficulty in familiarizing the 
environment as demonstrated by more spontaneous motor activity compared with WT 
mice. These findings suggest that TNF-α has a protective role for neurons after KA 
insult via TNFR1. The ability of TNF-α to induce changes in ion currents is linked to 
ATP release and may be causally related to the neuroprotective characteristic of TNF-α 
during excitotoxicity [158]. Moreover, the induction of neuronal apoptosis inhibitor 
protein (NAIP) gene may also contribute to the neuroprotective properties of TNF 
[116]. In addition, TNF-α clearly possesses the ability to simultaneously activate both 
cell death and survival pathways, and this balance ultimately determines whether TNF-
α promotes neurodegeneration or neuroprotection. Defining the dual role of TNF-α in 
the CNS may depend on determining which conditions amplify NF-κB survival 
pathway and which might attenuate NF-κB activity while simultaneously promoting 
other pro-apoptotic TNF-α signals [159]. 
          Microglia are the major producers of TNF-α in the brain and may play a role in 
certain pathological conditions in the brain [160]. TNF-α is a strong activator of 
microglia in vivo [161], an event that results in substantial microglial production of 
nitric oxide [162] as well as further TNF-α secretion [163]. In our present study, 
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TNFR1-/- mice showed an increased number of activated microglia on 8 days after KA 
treatment, although a decrease of activated microglia on day 3 after KA treatment was 
found, which seemed more likely to be the consequence of massive death of microglia 
following an earlier wave of activation induced by KA. Correspondingly, a slightly 
lower TNF-α production is found on day 3 after KA administration. This biphasic 
response of TNF-α and its receptor is in agreement with another study. Scherbel et al. 
reported that after cortical contusion for 24-48 h, TNF-α knockout mice recovered 
faster than the respective controls. However, between 1 and 4 weeks, TNF-α knockout 
mice demonstrated greater neurological dysfunction [164]. Together with our findings, 
it is concluded that TNF-α deficiency might exert a protective effect by limiting 
microglia recruitment at an early stage of neurodegeneration following KA 
administration, while later the microglia might increase as a reactive response to the 
injured neuronal cells in TNFR1-/- mice.  
          Activated microglia express CCR3 and other chemokine receptors, and migrate 
along the concentration gradient of chemokines into the inflammatory sites in the CNS 
[165]. On day 3 after KA administration, the increased CCR3 expression on CD11b 
positive microglia was shown in our TNFR1-/- mice compared with WT mice. Thereby 
more microglia may be attracted to the injured area with the consequence of microglial 
release of toxins to worsen the neuronal damage.  
          Astrocytes are the most numerous non-neuronal cells in the CNS. Astrogliosis is 
associated with neurotoxicity and strong neuronal activity [87, 166]. Excitotoxicity can 
lead to astrogliosis, a feature of KA-induced hippocampal injury secondary to neuronal 
injury. Astrogliosis is believed to be mainly neuroprotective [86]. In our study, KA 
treatment led to enhanced astrocytosis in TNFR1-/- mice when compared with WT 
mice. This suggests that a deficiency of TNFR1 may indirectly influence astrocyte 
activity.  
   Taken together, TNF-α might be detrimental at an early stage of KA-induced 
neurodegeneration by activating microglia. However, a beneficial effect of TNF-α via 
TNFR1 on neurons in KA-induced excitatory injury is suggested by comparison of 
clinical and histological changes between WT and TNFR1-/- mice. Our evidence 
highlights the complicated function of TNF-α, although the factors and pathways 
responsible for this beneficial effect remain to be resolved. 
 
   21 
4.2  STUDY II: GENDER DIFFERENCES IN SUSCEPTIBILITY TO KA-
INDUCED NEURODEGENERATION IN AGED C57BL/6 MICE 
     In the present study, we have observed that aged female mice were more 
sensitive to KA-induced excitotoxicity compared with aged males, adult females and 
adult male mice. When the mice were treated with 30 mg/kg bodyweight KA 
intranasally, only one out of five aged female mice survived. When the mice were 
treated with 20 mg/kg bodyweight KA intranasally, the aged female mice still 
displayed severe seizure activity and showed prominent hippocampal neuronal damage 
seven days after KA treatment. In addition, only KA-treated aged female mice 
exhibited differences from other three groups of mice in behavioral test, which also 
indicated that hippocampal functions in aged female mice were damaged more than the 
other mice [167, 168]. Additionally, the level of BDNF expression in the hippocampus 
of KA-treated aged female mice was significantly increased when compared with other 
groups of mice. 
          Gender differences in susceptibility to glutamate excitotoxicity have been 
discussed in the past few years. Our study evidenced that aged female C57BL/6 mice 
were highly sensitive to excitotoxic neurodegeneraion induced by KA. Some research 
groups reported aged-related sensitivity to excitotoxicity in male animals [127];  
however, these studies have included only male subjects. It is still uncommon for aged 
males and females to be compared in the same study. Besides the pivotal reason of the 
different strains of animals used, this discrepancy might be also due to different routes 
and doses of KA administration. The dose of KA we used in the present study was 
much lower than we applied in our previous studies [31], thus, only the mice with high 
sensitivity to KA insult could be induced severe clinical, pathological and behavioral 
changes. The mechanism behind gender disparity to KA exposure needs further 
investigation and whether altered estrogen levels in aged female animals contribute to 
neurodegenerative diseases is still controversial. Recent reports have showed that 
although estradiol administration in KA-treated rats has beneficial effects on cell 
survival, it has diverse effects on exploratory behavior, object, and spatial memory 
[169]. In vitro studies suggested that 17-beta estradiol and raloxifene, a selective 
estrogen receptor modulator, could alter microglial and astrocyte produced molecules 
involved in neuroinflammation and neurodegeneration [170]. However, ovariectomy 
proved to be ineffective in altering seizure incidence, latency, or severity after KA 
treatment [125]. 
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          Although a few studies indicated that aged rats were less susceptible to the 
excitotoxic effect of kainic and quinolinic acids [171], many researchers have shown an 
increased sensitivity of aged individuals to excitotoxic neurodegeneration. It has been 
reported that KA-induced response via AMPA receptors was greater in the aged than in 
the young rats [172]. The currents induced by AMPA displayed a significant increase 
with age, which might mediate neurotoxicity associated with age-related neuropathies 
[126]. Aged CA1 failed to exhibit any tolerance to domoic acid (DOM) following 
preconditioning [127]. Hesp and his colleagues also reported that the aged rats lost 
tolerance to KA administration which was triggered by a selective reduction in 
constitutive KA-sensitive G-protein activity [173].  
          The age-related increase of astrogliosis may be secondary to modest synaptic 
degeneration. The roles of astrocytes in neuronal trauma are complicated and seemingly 
contradictory. There is ample evidence to support a beneficial component of astrocyte 
reactivity as well as an inhibitory one [86, 174]. Further, these dual roles may be more 
critical in the aged animals [175]. 
          The trophic factors produced by activated astrocytes mainly include NGF, basic 
fibroblast growth factor (bFGF), BDNF and neuregulins [176]. The role of BDNF and 
NGF in maintaining survival and promoting plasticity of neurons in the CNS is well 
established. Our results showed that BDNF level in the hippocampus of aged female 
mice was remarkably higher than that of aged males after KA treatment, in agreement 
with the study by Matsuki et al which suggested that female animals were more 
sensitive to the induction of BDNF mRNA in the retrosplenial cortex by dizocilpine-
induced neurotoxicity [177]. Our previous studies found that on five days after KA 
treatment, the expression of most molecules (F4/80, MHCII, and iNOS) dropped to 
untreated levels, indicating a short time window of aggravating phase in our 
neurodegenerative model [69]. Seven days after KA administration, elevated BDNF 
levels in severe injured aged female mice may represent a compensatory mechanism to 
the greater damage. BDNF can suppress oxyradical production and stabilize cellular 
calcium homeostasis in neurons [178], while the mechanism whereby BDNF protects 
neurons against excitotoxic injury in vivo is not known. 
          In summary, our present results denote the disparity of aging and gender in KA-
induced hippocampal neurodegeneration. Aged female mice are more sensitive to KA-
induced excitotoxicity. 
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4.3 STUDY III: KA-INDUCED MICROGLIAL ACTIVATION IS 
ATTENUATED IN AGED IL-18 DEFICIENT MICE 
          We investigated the role of IL-18 in the pathogenesis of KA-induced excitotoxic 
neurodegeneration in the aged situation by using IL-18-deficient aged (18 to 19 months 
old) mice and age-matched WT mice. The study was motivated by the fact that most 
common neurodegenerative disorders such as AD and PD are typically diseases of 
higher ages and by the hypothesis that findings of KA-induced neurodegeneration of 
young individuals may deviate from findings in older subjects. Since previously we 
also found that aged female C57BL/6 mice were more sensitive to KA treatment than 
aged male mice [179], we performed this study on female animals.   
          Our results show that IL-18 deficiency does not influence susceptibility to KA-
induced injury in aged female mice, since KA-induced seizures, behavioral changes 
and histopathological changes including astrogliosis were similar in IL-18-/- mice and 
WT controls. However, we found also that aged IL-18-/- mice show lower microglial 
activation in response to KA than do WT mice as demonstrated by lower numbers of 
CD11b-positive and MHC-II-positive cells. On the other hand, in these activated 
microglia the percentages of TNF-α-, IL-6- and IL-10-positive cells were significantly 
higher in IL-18-/- mice than in WT mice. These results are in contrast to our previous 
findings in KA-induced excitotoxic neurodegeneration of IL-18-deficient young mice 
[32]. Young (6 to 8 weeks old) IL-18-/- mice were more sensitive to KA administration 
than age-matched animals with normal expression of IL-18. In that situation we 
concluded that excitotoxic injury in IL-18 deficient mice might be due to 
overcompensation by other microglia-derived, disease-promoting factors, of which IL-
12 is one candidate. Our present finding that aged IL-18-/- mice display similar 
susceptibility to KA treatment as WT mice might be due to the balancing influence of 
other microglia-derived cytokines such as TNF-α, IL-6 and IL-10.  
          However, we also found in young animals that exogenous IL-18 administration 
could aggravate KA-induced neurodegeneration, when high dose of IL-18 was applied 
[32]. A recent study of Jeon and co-workers gave hints in the same direction by 
showing that levels of IL-18 and its receptor in hippocampal homogenates increased 
from day 1 post-KA onward [122]. Other researchers have found that lower IL-18 
concentrations are associated with improved activities of daily living in 65- to 80-year-
old men, suggesting that IL-18 might play an active role in age-related functional 
impairment [180]. Moreover, increased concentrations of the proinflammatory 
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cytokines IL-1α, IL-18 and IFN-γ in hippocampus are accompanied by deficits in long-
term potentiation in older rats [181]. The imbalance between pro-inflammatory and 
anti-inflammatory cytokines in the aged brain significantly contributes to age-related 
deficits in synaptic function [182].  
          Upon neuronal injury, microglia, as the main effector cells of the immune system 
in the CNS, acquire changes in morphology and expression of surface antigens and 
soluble molecules [73].  In the present study, lower KA-induced microglial activation in 
the hippocampi of aged IL-18-/- mice was found compared with WT as detected by 
immunohistochemistry and flow cytometry. This finding was in agreement with studies 
of Sugama and co-workers, which showed that stress-induced microglial activation was 
reduced in IL-18-/- mice [183]. IL-18 null mice also showed diminished microglial 
activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine treatment [121]. Interestingly, even though the number of 
activated microglia was smaller in KA-treated IL-18-/- mice than in KA-treated WT 
mice, the proportion of microglia cells that expressed the cytokines TNF-α, IL-6 and 
IL-10 was higher in the KA-treated IL-18-/- mice, which might account for the similar 
neuropathological and clinical outcome of the IL-18-deficient, aged mice. 
            In conclusion, deficiency of IL-18 attenuates microglial activation in KA-
induced excitotoxicity in aged brain, while the net effects of IL-18 are balanced by 
other cytokines, such as TNF-α, IL-6 and IL-10. IL-18 may participate in KA-induced 
hippocampal neurodegeneration in young animals, but IL-18 does not seem to 
represent a key cytokine in this process in aged individuals. 
 
4.4 STUDY IV: IL-18 DEFICIENCY INHIBITS BOTH TH1 AND TH2 
CYTOKINE PRODUCTION BUT NOT THE CLINICAL SYMPTOMS IN 
EAN 
          IL-18 has been reported to serve as a link between innate and adaptive immune 
responses. But IL-18 does not seem to represent a key cytokine in our KA-induced 
neurodegenerative animal model. In the present study, we introduced another animal 
model-EAN, to further test the role of IL-18 in experimental neurodegenerative and 
neuroinflammatory disorders. EAN has been suggested to be associated with 
dysregulation of the cytokine network including a predominance of proinflammatory 
Th1 cytokines [150]. Previous studies pointed to a pathogenic role of IL-18 in EAN and 
its human analogue GBS [155, 184]. We found that IL-18-/-  mice were similar to WT 
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mice in clinical course and severity of disease. Also antigenically and mitogenically 
stimulated splenic MNC proliferation was not different between IL-18-/- mice and WT 
EAN mice. However, cells producing cytokines IFN-γ, IL-10 and IL-12 were decreased 
in the CE infiltrates of IL-18-/- EAN mice compared with WT EAN mice, suggesting 
that IL-18 may act as a co-inducer of both Th1 and Th2 cytokines in our EAN model.  
          Since a balance of cytokine production is likely to determine the outcome of 
EAN [150], the observed net effect of no influence of IL-18 deficiency on EAN 
severity may reflect the “new-level” balance of Th1 and Th2 cytokines in EAN. Our 
results are in accordance with the finding of Jiang et al. [185], who reported that 
experimental autoimmune uveitis (EAU) in IL-18 deficient mice was accompanied by 
decreased production of IFN-γ, TNF-α and IL-10 in supernatants of lymph node cell 
cultures. 
          Macrophages and T cells are the main components of infiltrates in the PNS of 
GBS and EAN [186]. Macrophages are the main source of TNF-α in the inflammatory 
process of both GBS and EAN [187]. Although IL-18 can promote TNF-α production 
[188] and a decreased TNF-α production has been found in supernatants of lymph node 
cell cultures in IL-18-/- mice with EAU [185] and collagen-induced arthritis [189], our 
data showed only an insignificant tendency of decreased TNF-α levels in the 
infiltrating cells of CE in IL-18-/- EAN mice. This indicates that TNF-α production in 
the inflamed nerves of EAN may not be dependent on IL-18 in contrast to IFN-γ, IL-12 
and IL-10 production. 
    In brief, IL-18 deficiency does not prevent mice from EAN despite decreased 
levels of Th1 and Th2 cytokines in IL-18 deficient EAN mice. These findings indicate 
that IL-18 is a co-inducer of both Th1 and Th2 cytokines in EAN and possibly in GBS 
as well as in other T-cell-mediated autoimmune diseases. 
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5 CONCLUSIONS 
 
1) TNF-α plays a protective role in KA-induced excitotoxic injury in brain through 
TNFR1 signalling.  
2) There is a disparity of aging and gender in response to KA-induced hippocampal 
neurodegeneration. Aged female mice are more sensitive to KA-induced 
excitotoxicity.  
3) Deficiency of IL-18 attenuates microglial activation in KA-induced 
excitotoxicity in aged brain, while the net effects of IL-18 are balanced by other 
cytokines, such as TNF-α, IL-6 and IL-10.  
4) IL-18 deficiency does not prevent mice from EAN despite decreased levels of Th1 
and Th2 cytokines.  
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